Hints and tips:
...Tony Blair to N.F.L star Tom Brady and his supermodel wife Giselle Bundchen....
...The letter was organised by Ken Chenault, former chief executive of American Express, and Ken Frazier, outgoing chief executive of Merck....
...A decade ago, the US pharmaceuticals company Merck paid $41bn to acquire Schering-Plough, consolidating and cutting thousands of jobs amid an industry crisis of innovation and confidence....
...Acalabrutinib was inherited by Merck when it bought Schering-Plough in 2009 but it later disposed of the drug....
...However, a Pfizer-Allergan tie-up, would be the first full-scale combination between two top-20 pharma groups since Pfizer bought Wyeth and Merck acquired Schering-Plough in 2009....
...It drives growth and attracts a wealth of global corporations, investors and charities....
...In pharmaceuticals, Fred Hassan received $189m when Schering Plough was bought by Merck, and Hank McKinnell got $188m when he left Pfizer, despite an investor campaign under the slogan “give it back, Hank...
...In 2009, the Securities and Exchange Commission subpoenaed several hedge funds seeking documents relating to the patent expiration-fuelled takeover boom of 2009 when Schering Plough combined with Merck and...
...In July Merck announced that it was cutting up to 13,000 jobs as it looked to realise the cost savings promised when it acquired Schering Plough, the pharmaceutical company, for $41bn in 2009....
...The Genentech deal, combined with the “megamergers” in the same year of Pfizer’s $68bn purchase of Wyeth and Merck’s of Schering-Plough for $41bn, was a recent high water mark in dealmaking in the healthcare...
...Merck has been looking to achieve the savings it promised when it acquired Schering Plough for $41bn in 2009....
...scale following a restructuring triggered by Merck’s purchase of Schering-Plough in 2008....
...Afterwards Merck, which acquired the company when it took over Schering-Plough, shrank its operations drastically....
...The action came in spite of Merck’s efforts to structure its acquisition of Schering-Plough legally as a reverse takeover to avoid breaking a change of ownership clause governing its target’s foreign sales...
...the joint venture after Merck’s purchase of Schering-Plough and its animal health division Intervet....
...In a deal that ends arbitration triggered by Merck’s $41bn takeover of Schering-Plough in 2009, the company has scaled back its control over Remicade and Simponi, the reformulated self-injected version....
...Mr Clark, who took charge in 2005, adopted a relatively low public profile while overseeing changes including the $49bn takeover last year of Schering-Plough; an expansion of partnerships and alliances with...
...On Thursday Merck took a $1.7bn charge related to lower expectations for Vorapaxar, which it obtained as part of its $41bn merger with Schering-Plough in 2009, after setbacks in certain clinical trials....
...In 2009, Merck completed a $41bn purchase of rival Schering-Plough which must still be integrated. The company is aiming for $3.5bn in annual savings by the end of 2012....
...Jeff Stute, currently co-head of North American M&A, will become head of the North America healthcare group, while Robbie Huffines, who advised Merck on its acquisition of Schering Plough and is working...
...J&J said arbitration hearings in a dispute over its rheumatoid arthritis drug Remicade triggered by Merck’s takeover of its partner Schering Plough last year had already been completed, and a decision could...
...In the US, Merck has announced plans to cut 15 per cent of the workforce, or 15,000 jobs, by 2012 in restructuring after buying Schering-Plough....
...Sales jumped from $6.1bn in the third quarter of 2009 to $11.1bn due to the impact of Merck’s $41bn acquisition of Schering-Plough that gave the company access to a wave of new drugs and experimental treatments...
...Pacific Scientific Aerospace is smaller than the K&F acquisition and, at 8.7 times ebitda, Meggitt does not appear to have overpaid....
...Sanofi-Aventis has agreed to pay the minimum $1bn discussed with Merck last year to recombine their assets after a restructuring triggered by Merck’s takeover of Schering-Plough....
International Edition